Table 2.
Adverse events
| Adverse events | Pemetrexed + cyclophosphamide (n=30) | Pemetrexed monotherapy (n=32) | ||
|---|---|---|---|---|
|
| ||||
| All grade (%) | Grade 3 to 4 (%) | All grades (%) | Grade 3 to 4 (%) | |
| Hematologic toxicity | ||||
| Anemia | 12 (40%) | 2 (7%) | 10 (31%) | 1 (3%) |
| Leukocytopenia | 2 (6%) | - | - | - |
| Neutropenia | 3 (10%) | - | - | - |
| Thrombocytopenia | 3 (10%) | 1 (3%) | - | - |
| Nonhematologic toxicity | ||||
| Skin rash | 5 (17%) | - | 19 (59%) | - |
| Fatigue | 11 (36.6%) | - | 14 (44%) | - |
| Anorexia | 6 (20%) | - | 10 (31%) | - |
| Nausea | 10 (33%) | 1 (3%) | 18 (56%) | 1 (3%) |
| Vomiting | 4 (13%) | - | 7 (22%) | - |
| Stomatitis | 3 (10%) | - | 9 (28%) | - |
| Constipation | 2 (7%) | 4 (12%) | - | |
| Diarrhea | 4 (13%) | - | 8 (25%) | - |
| Infection | 2 (7%) | - | 2 (6%) | - |
| Edema | 2(7%) | - | 3 (9%) | - |
Values are presented as number (%, rounded off).